NuGen M.D. Announces DTC Eligibility Within the United States

Rhea-AI Summary

NuGen Medical Devices Inc. has announced that its common shares received DTC full-service eligibility effective September 9, 2022. This milestone enhances the accessibility of its shares for U.S. investors, as they recently began trading on the OTCQB under the symbol NGMDF. DTC eligibility facilitates electronic clearing and settlement of transfers, marking a significant step in the company's growth strategy. NuGen specializes in needle-free technologies for medical delivery, with products like InsuJet™ and PetJet™, targeting diabetes and veterinary medicine.

Positive

• DTC eligibility enhances accessibility for U.S. investors.
• Trading commenced on OTCQB under symbol NGMDF.
• Focus on innovative needle-free technologies improves potential market reach.

Negative

• None.

TORONTO, ON / ACCESSWIRE / September 12, 2022 / NuGen Medical Devices Inc. (TSXV:NGMD)(OTCQB:NGMDF) ("NuGen'' or the "Company"), a leader in needle-free drug delivery, is pleased to announce that, effective September 9, 2022, its common shares have received Depository Trust Company ("DTC") full-service eligibility within the United States. The Company's common shares recently began trading on the OTCQB under the symbol ‘NGMDF' in the United States. The Company's common shares continue to trade on the TSX Venture Exchange in Canada under the symbol "NGMD".

"This is an important milestone for Nugen," said Michael Wright, CEO of NuGen. "Building on our recent OTCQB listing, DTC eligibility means that our stock will be even more accessible to trade for a broader range of U.S. investors."

DTC eligibility allows for book-entry and depository services at the Depository Trust Company for the Company's common shares, which will facilitate electronic clearing and settlement of transfers in the United States.

About NuGen Medical Devices

NuGen is an emerging specialty medical device company developing the next generation of needle-free technologies and other innovative medical delivery products. The company's products, which include the InsuJet™ and PetJet™ needle-free injection systems, are designed to improve the lives of millions of people and animals. NuGen continues to receive approval in numerous countries, including Canada. NuGen's products are designed for use in several important fields including, but not limited to, diabetes, veterinary medicine, and vaccines.

For More Information visit: www.nugenmd.com
Twitter: @NuGenMD
LinkedIn: https://www.linkedin.com/company/nugenmd/

For further information, please contact:

Michael Wright
President and CEO
NuGen Medical Devices Inc.
mw@nugenmd.com

Investor Relations Contact:
Kin Communications Inc.
NGMD@kincommunications.com
(604) 684-6730

Twitter: @KinComm

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this press release include the Company's 2022 objectives of securing additional distribution and sales agreements, making submissions for regulatory approvals and capitalizing on additional market opportunities. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.

SOURCE: NuGen Medical Devices

View source version on accesswire.com:
https://www.accesswire.com/715521/NuGen-MD-Announces-DTC-Eligibility-Within-the-United-States

FAQ

What is DTC eligibility for NuGen Medical Devices?

DTC eligibility allows NuGen's shares to be electronically cleared and settled in the U.S., making them more accessible to investors.

When did NuGen Medical Devices receive DTC eligibility?

NuGen Medical Devices received DTC eligibility on September 9, 2022.

What stock symbol does NuGen Medical Devices trade under in the U.S.?

NuGen Medical Devices trades under the symbol NGMDF on the OTCQB.

What are the key products of NuGen Medical Devices?

NuGen's key products include the InsuJet™ and PetJet™ needle-free injection systems.

How does DTC eligibility benefit NuGen Medical Devices?

DTC eligibility allows for easier trading and settlement of shares for a broader range of U.S. investors.